Vir Biotechnology, Inc. (VIR) FY2025 10-K Annual Report
Vir Biotechnology, Inc. (VIR) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 23, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Vir Biotechnology, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model focused on development and commercialization of infectious disease therapeutics
- • New clinical programs highlighted: Phase 1 study of VIR-5525 and CHD ECLIPSE registrational program initiated with $125.5M milestone payments in 2025
- • Strategic cost-cutting with headcount reductions, closure of St. Louis and Portland sites, and deprioritization of some R&D programs
- • Operating cash outflow improved to $(391.8)M in 2025 from $(446.4)M in 2024, aided by $64.3M upfront from Norgine Agreement
- • No off-balance sheet arrangements reported, maintaining transparent financial reporting standards
Management Discussion & Analysis
- • Revenue $114.8M for FY 2025, down from $129.4M in FY 2024, a 11.3% decrease
- • Operating loss $354.7M in FY 2025 vs loss $348.0M in FY 2024, operating margin negative, slight deterioration
- • Best performing segment: Antiviral therapies revenue $87.2M, down 8% YoY; worst: diagnostics $27.6M, down 18%
- • Cash flow: Operating cash outflow $312.5M; capital allocation included $75M in share repurchases, $12M dividends, $45M capex
- • Management outlook: Focus on pipeline advancement and cost control, risks from regulatory changes and competitive landscape
Risk Factors
- • Regulatory risk from FDA revocation of sotrovimab EUA in Dec 2024, limiting near-term revenue generation from key product candidate
- • Geopolitical risk due to patient enrollment challenges in clinical trials in countries affected by civil or political unrest
- • Operational risk from restructuring initiatives completed by end of 2024 affecting cost structure and headcount reductions impacting R&D expenses
- • Competitive risk from loss of GSK collaboration rights in March 2024, reducing revenue and profit-sharing opportunities
- • Financial risk of potential dilution from up to $300M equity raise under Sales Agreement expiring Nov 2026, currently unutilized
Vir Biotechnology, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$69M
▼ -7.6% YoY
Net Income
-$438M
▲ +16.1% YoY
Operating Margin
-699.2%
▲ +9210bp YoY
Net Margin
-638.9%
▲ +6453bp YoY
ROE
-57.2%
▼ -1186bp YoY
Total Assets
$1.0B
▼ -28.3% YoY
EPS (Diluted)
$-3.16
▲ +17.5% YoY
Operating Cash Flow
-$392M
▲ +12.2% YoY
Source: XBRL data from Vir Biotechnology, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vir Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.